U.S. Preventive Service Task Force Does Not Recommend PSA Screening for Prostate Cancer(8/6/2008) Members of the U.S. Preventive Services Task Force have concluded that there is still insufficient evidence to recommend PSA screening in men 75 years of age or younger. The details of these recommendations were published in the August 5, 2008 issue of the Annals of Internal Medicine.
New Analysis Suggests Finasteride Prevents Prostate Cancer Without Increased Risk of High-grade Cancers(6/18/2008) Researchers affiliated with the Finastride Prostate Prevention Trial have reported a re-analysis of data previously published in the July 17, 2003 issue of the New England Journal of Medicine. This new analysis suggests that treatment with finasteride for seven years reduced the incidence of prostate cancer by approximately 25% without increasing the incidence of high-grade cancers. These new data were included in four publications published online on May 18, 2008 in Cancer Prevention Research.
Specific Gene Expression Predicts Risk for Prostate Cancer(5/9/2008) Researchers from Barcelona, Spain, have reported that expression of the PTOV1 (prostate tumor overexpressed-1) gene helps predict the likelihood of the development of prostate cancer among men with high-grade prostatic intraepithelial neoplasia (HG-PIN). These results were recently published in the May 2008 issue of Clinical Cancer Research.
Differing Prostate Cancer Mortality Between United States and United Kingdom(4/28/2008) Researchers from the United Kingdom have reported that between 1994 and 2004 there has been a greater decline in prostate cancer deaths in the United States than in the United Kingdom. These authors speculated that this may be due to differences in PSA screening. The details of this study appeared in an early online publication in Lancet Oncology on April 17, 2008.
Fluctuation in Weight May Influence Risk Certain Cancers(4/10/2008) Researchers in Austria have reported that large weight gains or losses may influence an individual’s risk for developing certain types of cancer. Complete details of the study were published in the April 2008 issue of the Annals of Oncology.
MRI with Contrast Effective for Pelvic Lymph Node Staging of Prostate Cancer(8/25/2008) Researchers from the Netherlands have reported that MRI with non-specific contrast allows for omission of diagnostic pelvic lymph-node dissection in men at intermediate or high risk of having nodal involvement. The details of this study appeared in an early online publication in Lancet Oncology on August 18, 2008.
Watchful Waiting Versus Radical Prostatectomy: 11-year Follow-up(8/21/2008) Researchers affiliated with the Scandinavian Prostatic Cancer Group Study Number 4 have reported the following: “Radical prostatectomy reduces prostate cancer mortality and risk of metastases with little or no further increase in benefit 10 or more years after surgery.” The details of the 3rd report of this randomized trial appeared in an early online publication in the Journal of the National Cancer Institute on August 11, 2008.
Low Socioeconomic Status Increases Cancer Mortality(7/24/2008) Researchers affiliated with the Findings from the National Program Registries Patterns of Care Study have reported that low socioeconomic status is associated with a high mortality due to later diagnoses and less aggressive treatments for cancer. The details of this study were reported in the August 1, 2008 issue of Cancer.
Denosumab Improves Bone Density in Prostate Cancer Patients(7/16/2008) Amgen has reported that denosumab improved bone density and reduced the risk of vertebral fracture in men with nonmetastatic prostate cancer receiving androgen-deprivation therapy (ADT).
Study Questions Benefit of Androgen Deprivation Therapy for Localized Prostate Cancer(7/11/2008) Researchers from the Robert Wood Johnson Medical School have reported that primary androgen deprivation therapy (PADT) may not be associated with improved survival compared with conservative management of elderly men with localized prostate cancer. The details of this study appeared in the July 9, 2008 issue of the Journal of the American Medical Association.
MRI with Contrast Effective for Pelvic Lymph Node Staging of Prostate Cancer(8/25/2008) Researchers from the Netherlands have reported that MRI with non-specific contrast allows for omission of diagnostic pelvic lymph-node dissection in men at intermediate or high risk of having nodal involvement. The details of this study appeared in an early online publication in Lancet Oncology on August 18, 2008.
Watchful Waiting Versus Radical Prostatectomy: 11-year Follow-up(8/21/2008) Researchers affiliated with the Scandinavian Prostatic Cancer Group Study Number 4 have reported the following: “Radical prostatectomy reduces prostate cancer mortality and risk of metastases with little or no further increase in benefit 10 or more years after surgery.” The details of the 3rd report of this randomized trial appeared in an early online publication in the Journal of the National Cancer Institute on August 11, 2008.
Denosumab Improves Bone Density in Prostate Cancer Patients(7/16/2008) Amgen has reported that denosumab improved bone density and reduced the risk of vertebral fracture in men with nonmetastatic prostate cancer receiving androgen-deprivation therapy (ADT).
Radiation Therapy for Prostate Cancer Increases Incidence of AML(6/18/2008) According to a study presented at the 2008 meeting of the American Society of Clinical Oncology, the use of external beam radiation therapy (EBRT) for treatment of prostate cancer is associated with a twofold increase in the risk of developing acute myeloid leukemia (AML).
Fareston® Decreases Vertebral Fractures in Men with Prostate Cancer Receiving ADT(6/10/2008) Researchers from the Massachusetts General Hospital have reported that the administration of Fareston® (toremifene citrate) decreases the risk of new vertebral fractures in men with prostate cancer receiving androgen deprivation therapy (ADT). The details of this study were presented at the 2008, 99th annual meeting of the American Association for Cancer Research in San Diego, April 12-16.
Radiofrequency Ablation Effective for Lung Tumors(7/22/2008) Researchers involved in a multicenter international trial have reported that the use of radiofrequency ablation for the treatment of lung cancer or pulmonary metastases provides an effective and safe therapeutic option for selected patients. These results were recently published in the July 7, 2008 issue of Lancet Oncology.
Fareston® Decreases Vertebral Fractures in Men with Prostate Cancer Receiving ADT(6/10/2008) Researchers from the Massachusetts General Hospital have reported that the administration of Fareston® (toremifene citrate) decreases the risk of new vertebral fractures in men with prostate cancer receiving androgen deprivation therapy (ADT). The details of this study were presented at the 2008, 99th annual meeting of the American Association for Cancer Research in San Diego, April 12-16.
Differing Prostate Cancer Mortality Between United States and United Kingdom(4/28/2008) Researchers from the United Kingdom have reported that between 1994 and 2004 there has been a greater decline in prostate cancer deaths in the United States than in the United Kingdom. These authors speculated that this may be due to differences in PSA screening. The details of this study appeared in an early online publication in Lancet Oncology on April 17, 2008.
Whole Pelvic Radiotherapy Superior to Prostate Bed Radiation for High-Risk Prostate Cancer(8/30/2007) Researchers from Stanford University have reported that whole pelvic radiation results in superior biochemical relapse-free survival (bRFS) than radiation only to the prostate bed after prostatectomy for high-risk patients with prostate cancer. The details of this study appeared in the September 1, 2007 issue of the International Journal of Radiation Oncology*Biology*Physics.
Experienced Surgeons Have Improved Prostatectomy Outcomes(7/26/2007) Researchers from the Memorial Sloan-Kettering Cancer Center, the Cleveland Clinic and Wayne State University have reported that prostate cancer control improves with increasing experience of the surgeon. The details of this study appeared in an early on-line publication in the Journal of the National Cancer Institute on July 24, 2997.
Abiraterone, an Inhibitor of Cytochrome P 17, Effective in Hormone Refractory Prostate Cancer(7/30/2008) Researchers from the United Kingdom have reported that the selective inhibitor of CYP17, abiraterone acetate, may be effective for the treatment of hormone refractory prostate cancer (HRPC). These results were published early online in the Journal of Clinical Oncology on July 21, 2008.
Radiofrequency Ablation Effective for Lung Tumors(7/22/2008) Researchers involved in a multicenter international trial have reported that the use of radiofrequency ablation for the treatment of lung cancer or pulmonary metastases provides an effective and safe therapeutic option for selected patients. These results were recently published in the July 7, 2008 issue of Lancet Oncology.
Salvage Radiotherapy Improves Prostate Cancer-specific Survival(6/19/2008) Researchers from Johns Hopkins University and Duke University have reported that salvage radiotherapy following biochemical recurrence improves prostate cancer-specific survival in men with a PSA doubling time of less than six months. The details of this retrospective analysis were published in the June 18, 2008 issue of the Journal of the American Medical Association.
GVAX® Promising for Early-stage Locally Recurrent Prostate Cancer(4/30/2008) Researchers involved in a multicenter Phase I–II trial have reported promising activity of GVAX® in patients with locally recurrent prostate cancer who had not received hormone therapy. The details of this trial were presented at the 2008 annual meeting of the American Association for Cancer Research, April 12-18, in San Diego.
Differing Prostate Cancer Mortality Between United States and United Kingdom(4/28/2008) Researchers from the United Kingdom have reported that between 1994 and 2004 there has been a greater decline in prostate cancer deaths in the United States than in the United Kingdom. These authors speculated that this may be due to differences in PSA screening. The details of this study appeared in an early online publication in Lancet Oncology on April 17, 2008.
Patient Home
